Sign in
M

Mark

Financial Advisor at Stifel

London, GB

Mark Province is a Financial Advisor at Stifel in Oklahoma City, specializing in wealth management and personalized investment strategies for individual clients and small businesses. He works closely with a select roster of clients to construct tailored portfolios but does not cover publicly traded companies as an equity analyst or publish widely tracked research with performance metrics such as those found on analyst ranking platforms. Mark has built his career at Stifel, advancing as a trusted advisor known for his client-centric approach and commitment to long-term financial planning. He is registered with the requisite FINRA licenses, including Series 7 and 66, which enable him to offer a comprehensive range of investment and advisory services.

Mark's questions to Mirum Pharmaceuticals (MIRM) leadership

Question · Q3 2025

Mark inquired about Mirum's perspective on the optimal endpoint for Fragile X studies, given recent comments from Shionogi, and the implications for Mirum's newly initiated program. He also asked about potential safety risks, specifically GI side effects, for Volixibat in PSC patients who often have inflammatory comorbidities, and whether blinded data showed any material differences compared to PBC or Alagille.

Answer

CEO Chris Peetz deferred to CMO Joanne Quan for details. CMO Joanne Quan expressed confidence in Mirum's Fragile X program, citing strong preclinical data, successful engagement with the community and FDA, and awareness of endpoint validation requirements. Regarding PSC safety, she noted that the data monitoring committee has raised no issues or suggested protocol modifications, indicating comfort with the current safety profile, which is consistent with known IBAT inhibitor effects.

Ask follow-up questions

Fintool

Fintool can predict Mirum Pharmaceuticals logo MIRM's earnings beat/miss a week before the call

Let Fintool AI Agent track Mark for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free